Dr. Comenzo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
800 Washington St
Boston, MA 02111Phone+1 617-636-5000- Is this information wrong?
Education & Training
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
Boston University Medical CenterResidency, Internal Medicine, 1986 - 1989
Boston University School of MedicineClass of 1986
Certifications & Licensure
MA State Medical License 1988 - 2025
NY State Medical License 1998 - 2010- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Pathology Blood Banking/Transfusion Medicine
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2010-2014
- Boston Magazine Castle Connolly, 2009-2013
- America's Top Doctors for Cancer Castle Connolly, 2009-2013
- Join now to see all
Clinical Trials
- Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma Start of enrollment: 2000 Aug 01
- Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma Start of enrollment: 2000 Aug 01
- Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Start of enrollment: 2003 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 7 citationsBirtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.Morie A Gertz, Adam D Cohen, Raymond L Comenzo, Efstathios Kastritis, Heather J Landau, Edward N Libby, Michaela Liedtke, Vaishali Sanchorawala, Stefan Schönland, Ashu...> ;Blood. 2023 Oct 5
- 1 citationsDaratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.Kenshi Suzuki, Ashutosh D Wechalekar, Kihyun Kim, Chihiro Shimazaki, Jin Seok Kim, Takayuki Ikezoe, Chang-Ki Min, Fude Zhou, Zhen Cai, Xiaonong Chen, Shinsuke Iida, Na...> ;Annals of Hematology. 2023 Apr 1
- 9 citationsRelapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse.Parva Bhatt, Colin Kloock, Raymond Comenzo> ;Current Oncology. 2023 Feb 15
- Join now to see all
Abstracts/Posters
- Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus PhysicianÍs Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary...Raymond L Comenzo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optim...Raymond L Comenzo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- B-Cell Maturation Antigen (BCMA) in Systemic Light-Chain Amyloidosis (AL): Association with Disease Activity and Its Modulation with Gamma-Secretase InhibitionRaymond L Comenzo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Untangling Amyloidosis 201961st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Seeking AL Amyloidosis Very Early: The SAVE Trial - Identifying Clonal Lambda Light Chain Genes in Patients with MGUS or Smoldering Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
What Is Causing the National Blood Shortage?March 4th, 2022- What Doctors Want You to Know About the Potential Link Between COVID-19 and Blood TypeJune 24th, 2020
Experimental Drug Shows Promise for Rare Genetic Disorder – WebMDFebruary 11th, 2019
Hospital Affiliations
Tufts Medical CenterBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
